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S U M M A R Y
Objectives: The aims of this study were to evaluate oxidant and antioxidant status in patients with acute
brucellosis before and after therapy, and to determine whether this index could be used to monitor the
treatment of brucellosis.
Methods: Thirty patients with a diagnosis of acute brucellosis and 37 healthy volunteers were enrolled in
the study. Total antioxidant status (TAS) and total oxidant status (TOS) were measured in patients before
and after therapy, and an oxidative stress index (OSI) was calculated. These measurements were also
taken for the healthy control group and the values were compared.
Results: Plasma levels of TOS and OSIwere signiﬁcantly higher in patientswith brucellosis before therapy
as compared to the treated group (t: 11.19, p < 0.000 and t: 9.91, p < 0.000, respectively). After treatment,
TOS and OSI levels were lower, whereas in contrast, TAS levels were signiﬁcantly higher (t: 4.17,
p < 0.000). TOS and OSI levels were found to be signiﬁcantly higher in the patients before treatment than
in the control group (t: 15.01, p < 0.000 and t: 15.00, p < 0.000, respectively). TAS levels in patients before
treatment were lower than in the controls and the difference was signiﬁcant (t: 8.03, p < 0.000). TOS
and OSI levels were signiﬁcantly higher in the treated group than in the control group (t: 4.58, p < 0.000
and t: 9.91, p < 0.000, respectively). TAS levels in the treated group were lower than in the control group
and the difference was signiﬁcant (t: 3.02, p < 0.004).
Conclusion: Reduced TAS capacity and elevated TOS levels may lead to considerable oxidative stress in
brucellosis. Increased oxidative stress may cause severe oxidative damage in the body, and even though
this damage ameliorates considerably with 6 weeks of treatment, normal healthy levels are not attained.
In addition, it appears possible that these oxidant and antioxidant parameters could be used to monitor
treatment.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Human brucellosis, a zoonotic infection, remains a signiﬁcant
public health problem in areas of the world where Brucella
infections are endemic in food animals.1 Brucella strains are
facultative intracellular Gram-negative bacteria. They have the
capacity to survive and replicate for prolonged periods within host
macrophages and thus have the ability to produce chronic
infections.2 Themechanisms bywhich brucellae evade intracellular
killing arenotwell understood, but it has been reported that thehost
macrophage oxidative burst represents a primary mechanism that
controls the intracellular replication of brucellae.3 The bacteria are
internalized into phagocytic cells, such as polymorphonuclear* Corresponding author. Tel.: +90 414 3183120.
E-mail address: suda_tekinkoruk@yahoo.com (S.T. Koruk).
1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.01.009neutrophils (PMNs) and macrophages, and are killed by reactive
oxygen and nitrogen species.4
Reactive oxygen species (ROS) can be produced in all living
organisms as a result of normal aerobic metabolism, and levels
increase during inﬂammation. ROS lead to cell damage through
peroxidation of double-chain fatty acids, protein, and DNA.5–7
Free oxygen radicals may develop in tissues or cells and
participate in the pathogenesis of various diseases, including
chronic hepatitis C, cancer, and inﬂammatory diseases.8–10 In
brucellosis, stimulation of macrophages is a signiﬁcant stage in
the progress of the disease in which cells serve as an effector
system of cytokines, chemokines, and free radicals, such as nitric
oxide (NO). NO reacts with superoxide (O2
) to produce highly
damaging reactive nitrogen species (RNS). These molecules
induce programmed cell death, and apoptosis occurs.11 ROS that
develop at this stage are also used by leukocytes in the body’s
defense against bacterial infections.12ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Characteristics of the patients with acute brucellosis and the control group
Characteristic Acute brucellosis Control group
Gender (M/F) 15/15 20/17
Age (years) 22.0312.52 28.0512.19
BMI (kg/m2) 22.242.54 23.412.58
ESR (mm/h) 22.9010.70 17.598.45
CRP (mg/dl) (normal range 0.1–0.5) 3.522.06 0.100.14
ALT IU/l (normal range 5–41) 58.9750.70 24.5910.11
Results are mean standard deviation.
BMI, body mass index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein;
ALT, alanine aminotransferase.
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patients with acute brucellosis before and after therapy to establish
an oxidative stress index (OSI) and to determine whether this index
could be used for monitoring the treatment of brucellosis.
2. Materials and methods
2.1. Patient selection
This studywas carried out in the Infectious Diseases and Clinical
Microbiology Department, Harran University Medical Faculty,
between June 2009 and December 2009. Thirty patients with a
diagnosis of acute brucellosis and 37 healthy volunteers were
enrolled in the study. Written informed consent was obtained from
all participants, and the study protocol was approved by the Ethics
Committee of Harran University Medical Faculty.
In the patient group, acute brucellosis was diagnosed via clinical
symptoms and signs compatible with the disease (such as fever,
chills, and arthralgia) in conjunction with a Brucella standard tube
agglutinationtest titer1/160and/orBrucella sppgrowth incultures
of blood samples.13 The patients enrolled were non-smokers aged
between 15 and 65 years, who had a diagnosis of acute brucellosis
with symptoms initiating more than 8 weeks prior to enrollment,
with no complications due to brucellosis, no previous diagnosis of
brucellosis, and no diagnosis of any chronic disease. Healthy
volunteers comparable to the patient group in terms of age and
gender and with no chronic disease were enrolled as the control
group.
Patients diagnosed with brucellosis were treated for 6 weeks
(except for streptomycin, 21 days) with dual combinations of ﬁrst-
line drugs, namely doxycycline, rifampin, and streptomycin, in
accordance with the World Health Organization (WHO) recom-
mendations.14
To measure total antioxidant status (TAS) and total oxidant
status (TOS), two 10-ml samples of bloodwere obtained in the pre-
and post-treatment phases from the patient group and one sample
was obtained from the control group. Venous blood samples were
centrifuged for 10 min at 3500 rpm and immediately stored at
80 8C until analysis.
2.2. Measurement of total antioxidant status (TAS)
Serum TAS was determined using an automated measurement
method developed by Erel.15 This method utilizes the hydroxyl
radical, the most potent biological radical. In the assay, a ferrous
ion solution, which is present in reagent 1, is mixed with hydrogen
peroxide, which is present in reagent 2. Other potent radicals are
produced, such as brown dianisidinyl radical cation, which is
produced by the hydroxyl radicals. This method measures the
antioxidant effects of the sample against the potent free radical
reactions initiated by the hydroxyl radical. The assay has excellent
precision values of < 3%. The results are expressed as millimoles of
Trolox equivalent per liter (mmol Trolox equiv./l).
2.3. Measurement of total oxidant status (TOS)
TOS of serum was determined using an automated measure-
ment method developed by Erel.16 Oxidants present in the sample
oxidize the ferrous ion–o-dianisidine complex to ferric ion. The
oxidation reaction is enhanced by glycerol molecules, which are
abundantly present in the reaction medium. The ferric ion makes a
colored complex with xylenol orange in an acidic medium. The
color intensity, which can be measured spectrophotometrically, is
related to the total amount of oxidant molecules present in the
sample. The assay was calibrated with hydrogen peroxide, and theresults are expressed as micromoles of hydrogen peroxide
equivalents per liter (mmol H2O2 equiv./l).
2.4. Oxidative stress index (OSI)
The ratio of TOS to TAS yields the OSI, an indicator of the degree
of oxidative stress.15,16 For calculations, the resulting unit of TAS
was changed to mmol/l, and the OSI value was calculated
according to the following formula: OSI (arbitrary unit), TOS
(mmol H2O2 equiv./l), TAS (mmol Trolox equiv./l).
2.5. Statistical analysis
Statistical evaluation of the data was realized with SPSS 11.5
(SPSS for Windows, v. 11.5; SPSS Inc., Chicago, IL, USA). A paired
sample t-test was used in comparisons of pre- and post-treatment
variables. The Student’s t-test was used for comparisons of pre-
and post-treatment variables with the control group. The results
are shown as mean  standard deviation (SD). A p-value of <0.05
was accepted as signiﬁcant.
3. Results
The demographic characteristics and some laboratory results of
the 30 patients with acute brucellosis and the 37 healthy controls
are shown in Table 1. No statistically signiﬁcant difference was
observed when the study groups were compared in terms of age,
gender, or body mass index (BMI) (p > 0.05).
In this study, the most important risk factor for brucellosis
among patients was the consumption of fresh white (feta) cheese
(86.7%). In three patients (10.0%), a history of livestock farming and
close contact with animals was present. Patient symptoms
included fever (86.7%), arthralgia (66.7%), sweating (53.3%), and
headache (23.0%).
In case patients, the average erythrocyte sedimentation rate
(ESR) was 22.90  10.70 (range 8–51) mm/h, C-reactive protein
(CRP) was 3.52  2.06 (range 1.2–8.0) mg/dl, and alanine amino-
transferase (ALT) was 58.97  50.70 (range 14–194) IU/l (Table 1).
Elevated ESR, CRP, and ALT were observed in 43.3%, 60%, and 46.6% of
the patients, respectively. Anemiawas seen in 20% of the patients and
thrombocytopenia in 3.3%. There was growth of Brucella spp in blood
sample cultures in 33.3% of the patients.
Among patients with a diagnosis of brucellosis, 43.3% were
treated with streptomycin (1 g/day, 21 days) plus doxycycline
(200 mg/day, 6 weeks), 43.3% with rifampin (600 mg/day,
6 weeks) plus doxycycline (200 mg/day, 6 weeks), and 13.4% with
rifampin (600 mg/day, 6 weeks) plus co-trimoxazole (160 mg
trimethoprim  2/day, 6 weeks).
Plasma levels of TOS and OSI were signiﬁcantly higher in the
patientswith brucellosis before therapy than in those after therapy
(TOS t: 11.19, p< 0.000 and OSI t: 9.91, p < 0.000). In contrast, TAS
levels were signiﬁcantly lower in patients before therapy than in
those after therapy (t: 4.17, p < 0.000) (Table 2).
Table 2
Comparison of TAS, TOS, and OSI levels in patients with brucellosis before and after treatment and with control group levels
TAS TOS OSI
Mean SD t p Mean SD t p Mean SD t p
1. Before treatment 0.71 0.08 4.17 0.000 26.487.46 11.19 0.000 3.701.16 9.91 0.000
After treatment 0.83 0.15 10.874.04 1.38 0.70
2. Before treatment 0.70 0.10 8.03 0.000 26.487.46 15.01 0.000 3.701.16 15.00 0.000
Control group level 0.95 0.14 7.521.65 0.80 0.18
3. After treatment 0.83 0.15 3.02 0.004 10.874.04 4.58 0.000 1.38 0.70 9.91 0.000
Control group level 0.95 0.14 7.521.65 0.80 0.18
TAS, total antioxidant status (mmol Trolox equiv./l); TOS, total oxidant status (mmol H2O2 equiv./l); OSI, oxidative stress index (arbitrary units); SD, standard deviation.
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Figure 1. Oxidative stress index (OSI) levels in patients with brucellosis before and
after treatment and in the control group.
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and after treatment were individually compared with those of the
control group. TOS and OSI levels were found to be signiﬁcantly
higher in the patients before therapy than the control group levels
(TOS t: 15.01, p < 0.000 and OSI t: 15.00, p < 0.000). Patient TAS
levels before treatmentwere lower than those in the control group,
and the difference was signiﬁcant (t: 8.03, p < 0.000) (Table 2).
Post-treatment TOS and OSI levels were signiﬁcantly higher
than the control group levels (TOS t: 4.58, p < 0.000 and OSI t: 9.91,
p < 0.000). Post-treatment TAS levels were lower than the control
group levels, and the difference was signiﬁcant (t: 3.02,
p < 0.004) (Table 2).
Figure 1 showsOSI levels in patientswith brucellosis before and
after treatment and in the control group.
4. Discussion
Free oxygen radicals harm structural components such as lipids,
proteins, and nucleic acids, and thereby cause permanent damage.
In a number of diseases, increased ROS is not the primary cause of
the illness; it develops secondarily to the primary disorder and is
involved in pathogenesis.17 Whatever the reason, elevated ROS in
the cell decreases the probability of correct replication and
transcription by DNA repair enzymes and DNA polymerases.
When oxidative damage in DNA reaches a high level that is not
compatible with life, apoptosis occurs.7 There are studiesindicating that oxidative stress plays a role in the pathogenesis
of infectious diseases like hepatitis C, sepsis, and various bacterial
infections.18–20 In these cases, oxidant capacity was found to be
elevated and disruption in antioxidants was observed. In the
literature, the only study we could identify evaluating brucellosis
and oxidative status was conducted by Serefhanoglu et al.21 In that
work, the patient groupwas comparedwith a control group. On the
other hand, in the study presented here, we investigated
alterations in oxidative and antioxidative parameters between
pre- and post-treatment phases and sought to determine whether
these parameters could be used for monitoring treatment.
Oxidative stress occurs when the oxidative/antioxidative
balance is shifted towards the oxidative side in tissues and
organs.7 The levels of plasma antioxidant components can be
measured separately, but these measurements are impractical and
expensive.22 Various methods have been developed for measuring
total antioxidant status.23,24 Antioxidant activity indicates the
antioxidant characteristics of only one antioxidant, whereas total
antioxidant status represents the sum of all antioxidant char-
acteristics.25 In this study, a novel automated colorimetric
measurement method for TAS developed by Erel was used.15 This
method has advantages in comparison with other methods. It is
simple, cheap, reliable, and sensitive. It does not interact with
commonly occurring serum components such as serum lipids,
bilirubin, or anticoagulants.15
Brucella strains are able to alter the intracellular trafﬁcking of
host cell vacuoles and avoid the induction of inﬂammatory
responses. During their interactions with macrophages, these
bacteria encounter various environmental stresses. These stresses
include exposure to ROS and RNS.26 Brucella strains generate ROS
such as O2
 and H2O2 endogenously as a consequence of their
aerobic respiratory metabolism.27 Exogenous production of ROS
has also been shown to be important for the brucellacidal activity
of macrophages.3 Two major antioxidants with the capacity to
degrade H2O2 have been described in Brucella strains, the
periplasmic monofunctional catalase KatE and the peroxiredoxin
AhpC.28,29 Bacteria have compartmentalized defenses against ROS.
They have the ability to directly detoxify ROS and mechanisms for
indirectly avoiding oxidative damage.26
In this study, TAS levels in untreated patients with acute
brucellosis were found to be signiﬁcantly lower than those in post-
treatment patients and the levels in healthy individuals. This may
be due to the increased ROS that evolve from both endogenous and
exogenous pathways; it may also result from disruption of the
patient’s anti-oxidative defense mechanisms. In addition, as
indicated in the literature, we believe that the decrease may be
due to Brucella strains using antioxidants during direct or indirect
detoxiﬁcation of ROS.26,28 TAS levels were observed to be
signiﬁcantly higher after treatment. We were unable to ﬁnd any
studies indicating the effectiveness of oxidative stress markers for
monitoring treatment. In this study, we found that there were
signiﬁcant decreases in TOS and OSI levels in patients who were
treated successfully. The fact that both pre- and post-treatment
L. Karaagac et al. / International Journal of Infectious Diseases 15 (2011) e346–e349 e349valueswerehigher thanthecontrolgroupvalues indicates that some
damage is still present in the treated patients as compared to
individuals who do not have the disease. We believe that the
antioxidant capacity in the healthy control group is somewhat
damaged, although not to the extent it is in the patient groupwhen
treated. Another study conducted in patients with brucellosis and a
healthy control group reported ﬁndings similar to our results.21
There are some published experimental studies that have evaluated
oxidative events in the brucellosis model. One study has reported a
signiﬁcantdecrease inglutathioneperoxidase (GSH-Px) activity–an
antioxidant enzyme – at the beginning of Brucella infection, which
then continues because of the consumption of substrate of GSH-Px
by the pathogen-derived antioxidant enzymes.11 They also demon-
strated that pharmacological agents such as cisplatin, which inhibit
certain antioxidant enzyme activities in various conditions, as cited
by Erdogan et al.,11 may be considered to inﬂuence immune
responses and apoptosis tohelp eliminateBrucella that are localized
in the surviving host macrophages.
In conclusion, a decrease in TAS and an increase in TOSmay lead
to considerable oxidative stress in patients with brucellosis. In the
light of this information, it is possible to conclude that a high
oxidative stress occurs in brucellosis, which may cause severe
damage in the body, although this damage is repaired to a
considerable extent with treatment. Our data show that the
treatment protocol used in this study is quite effective for
decreasing oxidative stress, and that the ratio of TOS to TAS –
the OSI – could be used to monitor the treatment of brucellosis.
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